Login / Signup

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Alice Y HoStephen ShiaoSamantha A KobaldJonathan ChenDan G DudaAmy LyVeerle BossuytHae Lin ChoBrittany ArnoldSimon KnottGaorav P GuptaPhilomena McAndrewScott KarlanMourad TighiouartAlona MuzikanskyReva K BashoHeather L McArthur
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Preoperative RT with pembrolizumab is safe and results in high pCR rates and 3-year EFS, despite the lack of pembrolizumab during NAC. PD-L1 and TILs may be predictive biomarkers for preoperative anti-PD1/RT response. Reduction in TILs after adding RT to anti-PD1 highlights the importance of treatment sequencing.
Keyphrases